Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2016

Open Access 01-12-2016 | Case report

Prenatal sonographic diagnosis of fetal valproate syndrome: a case report

Authors: Norihiko Kikuchi, Satoshi Ohira, Ryoichi Asaka, Kyoko Tanaka, Akiko Takatsu, Tanri Shiozawa

Published in: Journal of Medical Case Reports | Issue 1/2016

Login to get access

Abstract

Background

Prenatal exposure of mother to valproate (VPA) causes teratogenic effects in the fetus, namely fetal valproate syndrome (FVS). We report a case of fetal valproate syndrome rarely diagnosed by prenatal sonographic examination.

Case presentation

Our patient was a female infant who was born to a 27-year-old nulliparous Japanese woman with epilepsy. The mother was diagnosed with infantile epilepsy at 1 year of age and had been using three antiepileptic drugs, including valproate, but preconceptional counseling was not performed. At 25 weeks of gestation, contracture of the fetal right wrist joint suggestive of a radial ray defect was observed by transabdominal ultrasonography. The fetus demonstrated growth retardation starting from 32 weeks of gestation. In addition, saddle nose as a facial anomaly was detected by three-dimensional ultrasound at 37 weeks of gestation. Accordingly, we suspected that the fetus had fetal valproate syndrome. At 39 weeks of gestation, the mother delivered an infant weighing 2056 g. The neonate had characteristic features of fetal valproate syndrome, such as facial configuration, slight muscular hypotonia of the whole body, breathing problems, right-hand articular contracture accompanied by radial ray defect, and cardiovascular malformation.

Conclusions

When obstetricians manage epileptic pregnant women without enough preconceptional counseling or adjustment for antiepileptic drugs, careful sonographic observation of the fetus is mandatory.
Literature
1.
go back to reference Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf. 2006;29:1–21.CrossRefPubMed Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy-related issues. Drug Saf. 2006;29:1–21.CrossRefPubMed
3.
go back to reference Juárez-Olguín H, Belmont-Gόmez A, Flores-Pérez J, Barranco-Garduño LM, Flores- Pérez C. Malformations in newborns associated to anticonvulsant consumption during pregnancy: experience in third level hospital of Mexico. Rev Invest Clin. 2008;60:15–20.PubMed Juárez-Olguín H, Belmont-Gόmez A, Flores-Pérez J, Barranco-Garduño LM, Flores- Pérez C. Malformations in newborns associated to anticonvulsant consumption during pregnancy: experience in third level hospital of Mexico. Rev Invest Clin. 2008;60:15–20.PubMed
4.
go back to reference Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609–17.CrossRefPubMed Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10:609–17.CrossRefPubMed
5.
go back to reference Mawhinney E, Craig J, Morrow J, Russell A, Smithson WH, Parsons L, et al. Levetriacetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80:400–5.CrossRefPubMed Mawhinney E, Craig J, Morrow J, Russell A, Smithson WH, Parsons L, et al. Levetriacetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology. 2013;80:400–5.CrossRefPubMed
6.
go back to reference Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999;33:145–58.CrossRefPubMed Kaneko S, Battino D, Andermann E, Wada K, Kan R, Takeda A, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999;33:145–58.CrossRefPubMed
7.
go back to reference Witters I, Van Assche F, Fryns JP. Nuchal edema as the first sign of fetal valproate syndrome. Prenat Diagn. 2002;22:834–5.CrossRefPubMed Witters I, Van Assche F, Fryns JP. Nuchal edema as the first sign of fetal valproate syndrome. Prenat Diagn. 2002;22:834–5.CrossRefPubMed
8.
go back to reference Kennelly MM, Moran P. A clinical algorithm of prenatal diagnosis of radial ray defects with two and three dimensional ultrasound. Prenat Diagn. 2007;27:730–7.CrossRefPubMed Kennelly MM, Moran P. A clinical algorithm of prenatal diagnosis of radial ray defects with two and three dimensional ultrasound. Prenat Diagn. 2007;27:730–7.CrossRefPubMed
9.
go back to reference Cook K, Prefumo F, Presti F, Homfray T, Campbell S. The prenatal diagnosis of Binder syndrome before 24 weeks of gestation: case report. Ultrasound Obstet Gynecol. 2000;16:578–81.CrossRefPubMed Cook K, Prefumo F, Presti F, Homfray T, Campbell S. The prenatal diagnosis of Binder syndrome before 24 weeks of gestation: case report. Ultrasound Obstet Gynecol. 2000;16:578–81.CrossRefPubMed
Metadata
Title
Prenatal sonographic diagnosis of fetal valproate syndrome: a case report
Authors
Norihiko Kikuchi
Satoshi Ohira
Ryoichi Asaka
Kyoko Tanaka
Akiko Takatsu
Tanri Shiozawa
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2016
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-016-1094-1

Other articles of this Issue 1/2016

Journal of Medical Case Reports 1/2016 Go to the issue